NCT03562494已完成1 期
A Randomized, Sham Surgery Controlled, Double-blind, Multi-center, Phase 1 Clinical Trial, Evaluating the Safety of VY-AADC02 in Moderate to Advanced Parkinson's Disease Patients With Motor Fluctuations
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 14
- 试验地点
- 11
- 主要终点
- Number of participants with treatment-emergent adverse events (TEAEs)
研究概览
简要总结
The objective of this study is to assess the safety of VY-AADC02 in participants with Parkinson's disease (PD) with motor fluctuations.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Care Provider, Outcomes Assessor)
入排标准
- 年龄范围
- 40 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Males and females, 40 to 75 years of age (inclusive)
- •Diagnosis of PD, consistent with United Kingdom Brain Bank Criteria
- •Motor responsiveness to dopaminergic therapy, demonstrated by improvement in Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS-UPDRS III score)
- •Disease duration from diagnosis of ≥4 years
- •An average of ≥3 hours of OFF time (that is, periods of insufficient control of motor PD symptoms) per day over 3 consecutive days as confirmed by the PD Diary
- •A stable, optimal regimen of Parkinson's medications including levodopa for at least weeks prior to screening evaluation. Participants must have a minimum duration of levodopa treatment of ≥1 year
- •In the judgment of the Investigator, stable Parkinson's features and symptoms for at least 4 weeks prior to screening evaluation
- •Agrees to defer any elective neurological surgery, including deep brain stimulation or ablation procedure for PD, levodopa or apomorphine infusion, or the addition of new dopaminergic formulations until after the study is completed, if medically appropriate
- •Ability to travel to study visits
排除标准
- •Atypical or secondary parkinsonism, including but not limited to symptoms believed to be due to trauma, brain tumor, infection, cerebrovascular disease, other neurological disease, or to drugs, chemicals, or toxins, as determined by the Investigator
- •Montreal Cognitive Assessment (MoCA) score <26
- •New or unstable psychiatric conditions (psychosis, depression) within 1 year of screening
- •Brain imaging abnormalities in the striatum or other regions that would substantially increase risk of surgery
- •Contraindication to magnetic resonance imaging (MRI) and/or gadolinium-based contrast agents
- •Prior brain surgery, infusion therapies or planned treatments that could complicate the study procedure or negatively impact study evaluations as determined from participant interview, screening MRI, or medical records
- •History of malignancy other than treated carcinoma in situ within 3 years of screening evaluation
- •Prior gene transfer, current treatment with any investigational agent (drug or device) within 2 months of screening evaluation, or participation or plans to participate in another research study
- •Severe, biphasic and/or uncontrolled dyskinesia
- •Disabling or uncontrolled impulse control disorders
研究组 & 干预措施
Sham (Placebo) Surgery
Placebo Comparator
Sham surgical procedure
干预措施: Sham (Placebo) Surgery (Other)
VY-AADC02 (NBIb-1817)
Experimental
Single administration of up to 3.6 x 10^12 vector genomes (vg) of VY-AADC02
干预措施: VY-AADC02 (Biological)
结局指标
主要结局
Number of participants with treatment-emergent adverse events (TEAEs)
时间窗: Up to 5 years after surgery
次要结局
未报告次要终点
研究者
研究点 (11)
Loading locations...
相似试验
已完成
1 期
Safety Study of AADC Gene Therapy (VY-AADC01) for Parkinson's DiseaseParkinson's DiseaseNCT01973543Neurocrine Biosciences15
已完成
1 期
Safety and Efficacy Study of VY-AADC01 for Advanced Parkinson's DiseaseIdiopathic Parkinson's DiseaseBasal Ganglia DiseaseBrain DiseasesCentral Nervous System DiseasesMovement DisordersNervous System DiseasesNeurodegenerative DiseasesParkinsonian DisordersParkinson's DiseaseNCT03065192Neurocrine Biosciences16
已完成
2 期
Phase 2, Double-blind, Randomized, Controlled Multi-center Clinical Trial of the Safety and Efficacy of Transplanted Fetal Porcine Cells in Patients With Parkinson's Disease.Parkinson's DiseaseNCT00226460Genzyme, a Sanofi Company
已完成
2 期
Study Assessing Efficacy and Safety of AKST4290 in Subjects With Parkinson's Disease on Stable Dopaminergic TreatmentParkinson DiseaseNCT04369430Alkahest, Inc.110
已完成
2 期
ADX48621 for the Treatment of Levodopa Induced Dyskinesia in Patients With Parkinson's DiseaseParkinson's DiseaseNCT01336088Addex Pharma S.A.83